98%
921
2 minutes
20
The aim of this study is to determine the pharmacokinetic change after intravenous administration of meloxicam at doses of 0.5, 1 and 2 mg/kg to sheep. The study was carried out on six Akkaraman sheep. Meloxicam was administered intravenously to each sheep at 0.5, 1, and 2 mg/kg doses in a longitudinal pharmacokinetic design with a 15-day washout period. Plasma concentrations of meloxicam were determined using the high performance liquid chromatography-ultraviolet, and pharmacokinetic parameters were evaluated by non-compartmental analysis. Meloxicam was detected up to 48 h in the 0.5 mg/kg dose and up to 96 h in the 1 and 2 mg/kg doses. As the dose increased from 0.5 to 2 mg/kg, terminal elimination half-life, and dose normalized area under the concentration versus time curve increased and total clearance decreased. Compared to the 1 mg/kg dose, it was determined that V decreased and C increased in the 2 mg/kg dose. Meloxicam provided the therapeutic concentration of >0.39 μg/mL reported in other species for 12, 48 and 96 h at 0.5, 1 and 2 mg/kg doses, respectively. These results show that meloxicam exhibits non-linear pharmacokinetics and will achieve unpredictable plasma concentrations when administered IV for a rapid effect at dose of ≥1 mg/kg in sheep.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jvp.13422 | DOI Listing |
Brain Behav
September 2025
Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran.
Introduction: Anxiety and stress are prevalent mental health issues. Traditional drug treatments often come with unwanted side effects and may not produce the desired results. As an alternative, probiotics are being used as a treatment option due to their lack of specific side effects.
View Article and Find Full Text PDFMicrob Drug Resist
September 2025
Drug Discovery Research, Wockhardt Research Centre, Wockhardt Ltd., Chhatrapati Sambhajinagar, India.
Cefepime (FEP), a fourth-generation cephalosporin combined with tazobactam (TAZ), a β-lactamase inhibitor, is being developed by Wockhardt as a pharmacodynamically optimized fixed dose combination (FEP-2 g + TAZ-2 g) for the treatment of multidrug-resistant Gram-negative infections. To undertake an exposure-response analysis for establishing pharmacokinetic (PK)/pharmacodynamic (PD) targets, it is crucial to characterize the PK profile of compounds in surrogate compartments, such as plasma and lung, in clinically relevant animal infection models used to evaluate efficacy. In the current study, PKs of FEP and TAZ were assessed in plasma and in epithelial lining fluid (ELF) of neutropenic noninfected, lung-infected, and thigh-infected mice.
View Article and Find Full Text PDFCardiol Young
September 2025
Department of Pharmacy, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.
Introduction: Neonates with ductal-dependent CHD rely on the patency of the ductus arteriosus to maintain circulation. Alprostadil is utilised to maintain ductal patency, although optimal dosing has not been determined. This study aims to describe alprostadil dosing in neonates with ductal-dependent CHD.
View Article and Find Full Text PDFJ Cardiovasc Electrophysiol
September 2025
City St George's University of London, London, UK.
Introduction: Etripamil is a fast-acting intranasally self-administered calcium-channel blocker developed for termination of paroxysmal supraventricular tachycardia (PSVT). Prior studies have demonstrated safety and efficacy of etripamil for PSVT termination following an initial medically supervised test dose during sinus rhythm. NODE-303 is an open-label, single-arm study that evaluated etripamil for multiple, at-home PSVT episodes, without test dose before first use.
View Article and Find Full Text PDFArch Pharm (Weinheim)
September 2025
Department of Biology, Faculty of Arts and Sciences, Cukurova University, Adana, Turkey.
l-Ascorbic acid exhibits paradoxical behavior as both antioxidant and pro-oxidant in cancer treatment, with mechanisms and optimal dosing remaining unclear. This in vitro study investigated l-ascorbic acid's effects on healthy lymphocytes and HL-60 leukemia cells using concentrations of 0.5-2 mg/mL for 6 and 24 h.
View Article and Find Full Text PDF